Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $342.00 Price Target at Scotiabank
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $345.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to ...
TD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)
In a report released yesterday, Ritu Baral from TD Cowen maintained a Hold rating on Spero Therapeutics (SPRO – Research Report). The company’s ...
pharmaphorum22h
Alnylam hails vutrisiran data, but investors seem sceptical
Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...
High Growth Tech Stocks In US With Promising Potential
Over the last 7 days, the United States market has experienced a 3.0% drop, yet it remains up by 7.5% over the past year with earnings anticipated to grow by 14% annually in the coming years. In this ...